Viron

Viron is a biopharmaceutical company that has been making groundbreaking strides since its establishment in 1990. The company's focus lies in discovering and developing high-value therapies for critical protein and lipid targets related to a range of health issues, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. This commitment to advancing medicine is driven by a fusion of cutting-edge technologies, such as genomics, gene editing, stem cell biology, patient-derived organoids, cryo-electron microscopy, synthetic biology, small molecule screening, and AI-powered image analysis through high-throughput screening. These innovations have significantly reshaped the landscape of drug discovery. Viron's success and potential have attracted significant attention from investors, culminating in a $50.00M Series B investment received on 08 December 2021. This round of funding brought in support from a diverse group of prominent financial backers, including B Capital Group, Xeraya Capital, BIVF, City Hill Ventures, Delos Capital, Korean Investment Partners, Lumira Ventures, Madison Partners, LYZZ CAPITAL, and Private Ventures Group ("PVG"). This strong financial backing serves as a testament to the confidence these reputable investors have in Viron's vision and capabilities in revolutionizing healthcare through innovative drug development.